Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mendel

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
Obesity Research|April 2, 1999
Sibutramine produces dose-related weight lossG A Bray, G L Blackburn, J M Ferguson, et al.
Journal of Clinical Microbiology|August 29, 2014
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibilityElizabeth M Streicher, Kashmeel Maharaj, Talita York, et al.
BMC Medicine|October 18, 2018
Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB studyM E Murphy, G H Wills, S Murthy, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 29, 2021
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohortsS Oelofse, A Esmail, A H Diacon, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
BMC Medicine|October 28, 2017
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosisMichael E Murphy, Patrick P J Phillips, Carl M Mendel, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
Obesity Research|April 2, 1999
Sibutramine produces dose-related weight lossG A Bray, G L Blackburn, J M Ferguson, et al.
Journal of Clinical Microbiology|August 29, 2014
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibilityElizabeth M Streicher, Kashmeel Maharaj, Talita York, et al.
BMC Medicine|October 18, 2018
Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB studyM E Murphy, G H Wills, S Murthy, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 29, 2021
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohortsS Oelofse, A Esmail, A H Diacon, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
BMC Medicine|October 28, 2017
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosisMichael E Murphy, Patrick P J Phillips, Carl M Mendel, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Pageof 12